In adult patients with septic shock who remain dependent on high‑dose vasopressors despite conventional resuscitation, source control, and antimicrobial therapy, what is the role of blood purification systems—including continuous renal replacement therapy with adsorptive hemofilters, polymyxin‑B hemoperfusion, and cytokine‑adsorption cartridges—and how should they be initiated and managed?

Blood Purification in Septic Shock: Current Evidence Does Not Support Routine Use

The 2016 Surviving Sepsis Campaign guidelines explicitly state "We make no recommendation regarding the use of blood purification techniques" in septic shock, and this neutral stance remains the most defensible position despite emerging data. 1

Guideline-Based Framework

The absence of a recommendation in the most widely adopted sepsis guidelines reflects insufficient evidence to establish benefit on mortality, morbidity, or quality of life. The guidelines prioritize:

• First-line management: Fluid resuscitation (30 mL/kg crystalloids), norepinephrine as primary vasopressor, source control, and appropriate antimicrobials 1
• No role for low-dose dopamine for renal protection (strong recommendation against) 1
• Blood purification: Explicitly neutral—neither recommended nor contraindicated 1

Emerging Research Evidence: Promising but Inconsistent

Polymyxin B Hemoperfusion (PMX-HP)

The 2026 TIGRIS trial represents the highest-quality recent evidence 2:

• Population: Endotoxic septic shock (endotoxin activity 0.60-0.89), multiorgan failure, vasopressor-dependent
• Intervention: Two 90-120 minute PMX-HP sessions, 22 hours apart
• Results:
  • 28-day mortality: 39% (PMX-HP) vs 45% (control); 95.3% posterior probability of benefit
  • 90-day mortality: 99.4% posterior probability of benefit (OR 0.54)
  • Critical limitation: Open-label design, Bayesian analysis dependent on prior assumptions from earlier trials

However, real-world data contradicts this optimism:

• A 2025 Taiwanese cohort found PMX-HP did not reduce 28-day mortality in routine practice; post-PMX-HP vasopressor escalation predicted death 3
• A 2024 Korean study showed faster vasopressor weaning but no mortality benefit 4

Hemoadsorption with CRRT

CytoSorb and oXiris filters show conflicting results:

• A 2024 Israeli study (n=76) found hemoadsorption + CRRT reduced ICU mortality (34% vs 66%, p=0.008) and 30-day mortality 5
• A 2026 comparative study found no difference between CytoSorb+CRRT and oXiris-CRRT in vasopressor-free days, mortality, or ICU outcomes 6

Clinical Algorithm for Decision-Making

When to Consider Blood Purification (Off-Guideline, Experimental)

Only consider in this specific scenario:

1. Refractory shock despite:
   • Adequate fluid resuscitation (≥30 mL/kg crystalloids)
   • High-dose norepinephrine (>0.5 mcg/kg/min) + second vasopressor
   • Source control achieved
   • Appropriate antimicrobials administered
2. Multiorgan failure with acute kidney injury requiring CRRT
3. Documented high endotoxin activity (0.60-0.89 units) if PMX-HP considered
4. Within 24 hours of shock onset (earlier intervention theoretically more beneficial)

Specific Modality Selection

If pursuing blood purification (acknowledging lack of guideline support):

• PMX-HP: Only if endotoxin activity measured and elevated; two sessions 22 hours apart; requires specialized cartridge and training 2
• Hemoadsorption (CytoSorb) + CRRT: If CRRT already indicated for AKI; may reduce vasopressor requirements faster 5
• oXiris-based CRRT: Alternative to CytoSorb if available; comparable outcomes 6

Contraindications and Cautions

• Do not delay source control or antimicrobials to initiate blood purification
• Do not use as monotherapy or substitute for standard resuscitation
• Monitor closely for treatment-related adverse events (catheter complications, hemodynamic instability during therapy) 2
• Recognize that vasopressor escalation post-treatment predicts poor outcome 3

Critical Pitfalls

1. Overinterpretation of surrogate endpoints: Lactate reduction and faster vasopressor weaning do not guarantee mortality benefit 6, 4
2. Selection bias in observational studies: Sicker patients may receive blood purification, confounding outcomes 5, 3
3. Resource allocation: These therapies are expensive, labor-intensive, and divert resources from proven interventions
4. False hope: Families may perceive blood purification as "doing everything possible" when evidence of benefit is marginal at best

Practical Reality

In routine clinical practice, blood purification should not be initiated for septic shock outside of clinical trials or highly selected cases in centers with expertise. The 2016 guideline's neutral stance remains appropriate given:

• Inconsistent mortality data across studies
• High cost and complexity
• Lack of validated patient selection criteria beyond the narrow TIGRIS population 2
• Risk of delaying or de-emphasizing proven therapies

If CRRT is already required for AKI, using hemoadsorptive filters (oXiris, CytoSorb) represents a reasonable option given comparable safety profiles and potential (though unproven) benefit 6, 5. This adds minimal additional risk to necessary renal support.

The multimodal approach described in case reports 7 remains experimental and cannot be recommended outside of salvage scenarios in tertiary centers with multidisciplinary expertise.